Clinical Trial Update: To Evaluate the Influence of the A118G Polymorphism in the mu Opioid Receptor Gene (OPRM1) on Effects of GSK1521498 and Naltrexone on Physiological and Behavioural Markers of Brain Function in Healthy Social Drinkers [Phase 1]

View source ↗

Summary

A Phase 1 pharmacogenetic study evaluating whether the A118G polymorphism in OPRM1 influences physiological and behavioural effects of GSK1521498 and naltrexone…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alcohol Use Disorder

Drugs mentioned

• GSK1521498 (GSK1521498)
• Naltrexone (Naltrexone)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Alcoholism | Phase 1 | Status: COMPLETED